Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1945 20
1946 92
1947 80
1948 83
1949 82
1950 82
1951 91
1952 98
1953 103
1954 88
1955 107
1956 92
1957 82
1958 104
1959 130
1960 125
1961 117
1962 126
1963 172
1964 206
1965 207
1966 171
1967 212
1968 249
1969 295
1970 307
1971 324
1972 449
1973 447
1974 556
1975 582
1976 617
1977 687
1978 842
1979 962
1980 959
1981 1034
1982 1275
1983 1279
1984 1701
1985 1794
1986 1804
1987 1830
1988 1936
1989 2174
1990 2336
1991 2321
1992 2452
1993 2381
1994 2447
1995 2588
1996 2718
1997 2809
1998 2726
1999 2966
2000 3254
2001 3414
2002 3539
2003 3574
2004 3855
2005 4341
2006 4605
2007 4691
2008 4766
2009 4985
2010 5404
2011 5859
2012 6218
2013 6322
2014 6130
2015 6227
2016 5890
2017 5675
2018 5748
2019 5922
2020 6318
2021 6053
2022 5931
2023 5678
2024 5796
2025 6305
2026 3283

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173,585 results

Results by year

Filters applied: . Clear all
Page 1
Oxaliplatin as a radiosensitizing agent in rectal cancer.
Huerta S, Hrom J. Huerta S, et al. Anticancer Drugs. 2011 Apr;22(4):317-23. doi: 10.1097/CAD.0b013e328343e076. Anticancer Drugs. 2011. PMID: 21285866 Review.
Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensi …
Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly …
Nanoparticle-Based Radiosensitization.
Kempson I. Kempson I. Int J Mol Sci. 2022 Apr 29;23(9):4936. doi: 10.3390/ijms23094936. Int J Mol Sci. 2022. PMID: 35563326 Free PMC article.
Nanoparticle-Based Radiosensitization.
Kempson I. Kempson I. Int J Mol Sci. 2020 Apr 20;21(8):2879. doi: 10.3390/ijms21082879. Int J Mol Sci. 2020. PMID: 32326054 Free PMC article.
Radiosensitisers.
[No authors listed] [No authors listed] Lancet. 1972 Sep 23;2(7778):638-40. Lancet. 1972. PMID: 4116783 No abstract available.
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP. Mardjuadi FI, et al. Target Oncol. 2015 Sep;10(3):375-83. doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11. Target Oncol. 2015. PMID: 25304881 Clinical Trial.
Our goal was to optimize the radiosensitizing potential of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, when given concomitantly with preoperative radiotherapy in KRAS wild-type locally advanced rectal cancer (LARC). ...
Our goal was to optimize the radiosensitizing potential of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, when g …
In Vivo Cytotoxic, Genotoxic and Radiosensitizing Effects of Clofarabine.
Quezada-Vidal J, Cruz-Vallejo V, Ortiz-Muñiz R, Cervantes-Ríos E, Morales-Ramírez P. Quezada-Vidal J, et al. In Vivo. 2024 Jul-Aug;38(4):1719-1730. doi: 10.21873/invivo.13622. In Vivo. 2024. PMID: 38936939 Free PMC article. Review.
BACKGROUND/AIM: ClFdA is a second-generation antineoplastic agent that has demonstrated significant anticancer activity, particularly against acute lymphoblastic leukemia and has been shown to have radiosensitizing activity. The aim of the study was to explore the g …
BACKGROUND/AIM: ClFdA is a second-generation antineoplastic agent that has demonstrated significant anticancer activity, particularly …
Radiosensitisation.
Adams GE. Adams GE. Lancet. 1972 Oct 28;2(7783):921. doi: 10.1016/s0140-6736(72)92555-x. Lancet. 1972. PMID: 4116618 No abstract available.
Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Fernandes JM, Jandrey EHF, Koyama FC, Leite KRM, Camargo AA, Costa ÉT, Perez RO, Asprino PF. Fernandes JM, et al. Dis Colon Rectum. 2020 Jul;63(7):918-926. doi: 10.1097/DCR.0000000000001626. Dis Colon Rectum. 2020. PMID: 32229782
OBJECTIVE: The purpose of this study was to evaluate the radiosensitizing effects of metformin in vitro and in vivo and compare it with a standard combination of radiation/5-fluorouracil. ...Metformin is an attractive alternative radiosensitizing agent to be …
OBJECTIVE: The purpose of this study was to evaluate the radiosensitizing effects of metformin in vitro and in vivo and compare it wi …
173,585 results
You have reached the last available page of results. Please see the User Guide for more information.